MagForce Valuation
Is MF6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MF6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MF6 (€0.12) is trading below our estimate of fair value (€3.45)
Significantly Below Fair Value: MF6 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MF6?
Key metric: As MF6 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is MF6's PS Ratio? | |
|---|---|
| PS Ratio | 3.3x |
| Sales | €1.08m |
| Market Cap | €3.56m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 27x |
| Enterprise Value/EBITDA | -5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MF6's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.8x | ||
AUG Audientes | 12.6x | n/a | €6.9m |
GME Geratherm Medical | 0.8x | 1.9% | €15.1m |
AAQ1 aap Implantate | 1.8x | n/a | €22.4m |
PUS PULSION Medical Systems | 3.8x | n/a | €134.4m |
MF6 MagForce | 3.3x | 50.9% | €3.6m |
Price-To-Sales vs Peers: MF6 is expensive based on its Price-To-Sales Ratio (3.3x) compared to the peer average (1.2x).
Price to Sales Ratio vs Industry
How does MF6's PS Ratio compare vs other companies in the DE Medical Equipment Industry?
Price-To-Sales vs Industry: MF6 is good value based on its Price-To-Sales Ratio (3.3x) compared to the European Medical Equipment industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is MF6's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.3x |
| Fair PS Ratio | 1.3x |
Price-To-Sales vs Fair Ratio: MF6 is expensive based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (1.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CVS Health
US$66.9b
Provides health solutions in the United States.
CVS
US$50.67
7D
-2.6%
1Y
-18.8%
Fagron
€1.4b
A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
4A5
€18.54
7D
-2.3%
1Y
6.7%
Shandong Weigao Group Medical Polymer
HK$20.4b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.53
7D
-7.9%
1Y
-41.0%